Storyline
Pharma industry consolidation and obesity drug competition
Major pharmaceutical companies are pursuing growth through both mergers (AstraZeneca-Bristol Myers Squibb talks on a $400 billion deal) and competition in high-demand therapeutic areas, particularly obesity drugs where Eli Lilly and Novo Nordisk are battling for market dominance. The sector is experiencing significant financial and strategic shifts driven by blockbuster drug demand and company valuations.
AstraZenecaBristol Myers SquibbEli LillyNovo Nordisk
2026-08-05
- How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
- Amgen is raising its outlook after beating earnings and dropping a weight loss drug
- Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars
- Eli Lilly beat earnings and raised its forecast as weight loss drug sales surged
- CVS Health's profit nearly tripled as it launched an Eli Lilly weight loss drug deal
- Lilly’s revenue soars 48%, driven by demand for its GLP-1s
- Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
- Novo Nordisk's raised forecast fails to change the debate over its obesity business